Ario Pharma Commences Phase 2a Trial Of TRPV1 Inhibitor For Cough Associated With Chronic Obstructive Pulmonary Disease
2/11/2014 9:57:45 AM
CAMBRIDGE, England--(BUSINESS WIRE)--Ario Pharma Ltd, the Cambridge biopharmaceutical company developing innovative new approaches to treat respiratory disease, announced today that it has commenced a Phase IIa study of its TRPV1 antagonist, XEN-0501, for the treatment and prevention of cough in patients with chronic obstructive pulmonary disease (COPD). Persistent cough in COPD and other respiratory conditions present as a huge unmet medical need, with novel therapies urgently needed to improve the quality of life of patients.
Help employers find you! Check out all the jobs and post your resume.
comments powered by